Athletes use our infusions to replenish lost fluids and bounce back from their toughest workouts
Semaglutide reduced systolic blood pressure by 3.3 mm Hg, high-sensitivity C-reactive protein by 37.8%, and improved lipid profilesall achieved on top of high baseline rates of evidence-based cardiovascular therapies (90% on statins, 86% on antiplatelet agents).[1] These pleiotropic effects likely contribute to cardiovascular risk reduction through mechanisms distinct from adiposity changes, supporting the reconceptualization of GLP-1 receptor agonists as cardiovascular disease-modifying agents rather than simply weight-loss medications
Unlike single-action drugs, retatrutide targets multiple receptors in the body, including GLP-1, GIP, and glucagon receptors
A provider planning for that reality discusses maintenance dosing, transition protocols, and realistic expectations about post-treatment weight stability during your initial consultation
John Mulvey, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark
